Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
复制标题
DOI:
10.1186/s12885-023-11613-8
复制
发表时间:
2023-12-06
期刊:
影响因子:
3.8
通讯作者:
Li, Jian
中科院分区:
文献类型:
--
作者:
Zhao, Jiali;Lin, En;Bai, Zirui;Jia, Yingbin;Wang, Bo;Dai, Yihua;Zhuo, Wenfeng;Zeng, Guifang;Liu, Xialei;Cai, Chaonong;Li, Peiping;Zou, Baojia;Li, Jian
Due to the high drug resistance of hepatocellular carcinoma (HCC), sorafenib has limited efficacy in the treatment of advanced HCC. Cancer-associated fibroblasts (CAFs) play an important regulatory role in the induction of chemoresistance. This study aimed to clarify the mechanism underlying CAF-mediated resistance to sorafenib in HCC. Immunohistochemistry and immunofluorescence showed that the activation of CAFs was enhanced in HCC tissues. CAFs and paracancerous normal fibroblasts (NFs) were isolated from the cancer and paracancerous tissues of HCC, respectively. Cell cloning assays, ELISAs, and flow cytometry were used to detect whether CAFs induced sorafenib resistance in HCC cells via CXCL12. Western blotting and qPCR showed that CXCL12 induces sorafenib resistance in HCC cells by upregulating FOLR1. We investigated whether FOLR1 was the target molecule of CAFs regulating sorafenib resistance in HCC cells by querying gene expression data for human HCC specimens from the GEO database. High levels of activated CAFs were present in HCC tissues but not in paracancerous tissues. CAFs decreased the sensitivity of HCC cells to sorafenib. We found that CAFs secrete CXCL12, which upregulates FOLR1 in HCC cells to induce sorafenib resistance. CAFs induce sorafenib resistance in HCC cells through CXCL12/FOLR1. The online version contains supplementary material available at 10.1186/s12885-023-11613-8.
登录
查看更多内容
影响因子:
5.6
作者:
Khare T;Bissonnette M;Khare S
通讯作者:
Khare S
DOI:
10.1158/1541-7786.mcr-12-0307
发表时间:
2012-11
期刊:
Molecular cancer research : MCR
影响因子:
--
作者:
Karagiannis GS;Poutahidis T;Erdman SE;Kirsch R;Riddell RH;Diamandis EP
通讯作者:
Diamandis EP
DOI:
10.1016/j.ijbiomac.2018.10.212
发表时间:
2019-03-01
影响因子:
8.2
作者:
Gao, Dekun;Tang, Tianchi;Li, Shiting
通讯作者:
Li, Shiting
DOI:
10.1084/jem.20131195
发表时间:
2013-12-16
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Lotti F;Jarrar AM;Pai RK;Hitomi M;Lathia J;Mace A;Gantt GA Jr;Sukhdeo K;DeVecchio J;Vasanji A;Leahy P;Hjelmeland AB;Kalady MF;Rich JN
通讯作者:
Rich JN
DOI:
10.1002/cac2.12414
发表时间:
2023-04
期刊:
Cancer communications (London, England)
影响因子:
--
作者:
通讯作者:
--